Company profile

Compass Pathways PLC

Pipeline2 assets

COMP360COMP360 / synthetic psilocybin treatment / Mental health
Treatment-resistant depressionPhase 3NDA rolling submission underwayUSUKPost-traumatic stress disorderPhase 2b/3IND accepted; trial initiation enabledUSAnorexia nervosaPhase 2
Prodrug programmeprodrug programme

Latest news16 items

May 28, 2026

Compass Pathways Elects Kathleen Tregoning to Board of Directors

May 26, 2026

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

May 14, 2026

Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026

May 13, 2026

Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights

May 6, 2026

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026

May 6, 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 24, 2026

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

Apr 21, 2026

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments

Apr 20, 2026

Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 2026

Apr 18, 2026

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

Apr 14, 2026

Compass Pathways Announces U.S Grant Program for the Creation of Post-Approval COMP360 Provider Training

Apr 8, 2026

Compass Pathways to Attend Needham Virtual Healthcare Conference on April 14, 2026

Apr 7, 2026

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 24, 2026

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

Mar 12, 2026

Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

Feb 26, 2026

Compass Pathways Announces Exercise of $200 Million in Outstanding Warrants

Compass Pathways PLC • Endpoint Arena